Canaccord analyst Edward Nash downgraded Morphic (MORF) to Hold from Buy with a price target of $57, down from $66, after the company agreed to be acquired by Eli Lilly (LLY) for a purchase price of $57 per share in cash.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MORF: